Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials

March 29, 2021

Nolasiban

G Griesinger, C Blockeel, P Pierzynski, H Tournaye, H Višňová, A Humberstone, P Terrill, O Pohl, E Garner, J Donnez, E Loumaye
Human Reproduction, Volume 36, Issue 4, April 2021, Pages 1007–1020

Read more

Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers

March 22, 2021

Nolasiban

Jörg Täubel, Ulrike Lorch, Christopher S. Spencer, Anne Freier, Dorothée Camilleri, Dilshat Djumanov, Georg Ferber, Line Marchand, Jean-Pierre Gotteland & Oliver Pohl

Scientific Reports 11, Article number: 6404 (2021)

Read more

The use of nolasiban, a novel oxytocin receptor antagonist, prior to embryo transfer: does it help?

December 7, 2020

Nolasiban

Ernest Loumaye, MD, PhD

19th World Congress of Gynecological Endocrinology (On Line Congress 2-5 December 2020, available until 15 April 2021)

Abstract on p. 39 – part of SYMP19: Recent development in IVF

Gynecological and Reproductive Endocrinology and Metabolism 2020; Supplement 1 – Book of abstracts

Read more

The effect of the oral oxytocin antagonist, nolasiban, on pregnancy rates in women undergoing embryo transfer following IVF

October 22, 2020

Nolasiban

Georg Griesinger, MD, PhD; Jacques Donnez, PhD, MD; Andrew Humberstone, PhD; Paul Terrill, PhD; Oliver Pohl, DVM, MPH, MSc; Elizabeth Garner, MD, MPH; Ernest Loumaye, MD, PhD

ASRM 2020 Virtual Congress, October 2020

Poster session, abstract – Poster P. 482, page e303

Fertility and Sterility, Volume 114, No. 3, Supplement, September 2020, Poster P-482, page e303

Read more

Efficacy and safety of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids: Results from two Phase 3 randomized clinical trials

Linzagolix

Elizabeth A. Stewart, MD; Hugh S. Taylor, MD; Robert N. Taylor, MD, PhD; Jacques Donnez, PhD, MD; Elke Bestel, MD; Jean-Pierre Gotteland, PhD; Andrew Humberstone, PhD; Elizabeth Garner, MD, MPH

ASRM 2020 Virtual Congress, October 2020

Poster session, Late-breaking abstract – Poster P. 930, page e527

Fertility and Sterility, Volume 114, No. 3, Supplement, September 2020, Poster session, Late-breaking abstract – Poster P. 930, page e527

Read more

Linzagolix may address the long-term treatment needs of women with uterine fibroids who have contraindications to hormonal add-back therapy: results from two Phase 3 randomized clinical trials

Linzagolix

Linda D. Bradley, MD; Erica E. Marsh, MD, MSCI, FACOG; Elizabeth Garner, MD, MPH

ASRM 2020 Virtual Congress, October 2020

Poster session, Late-breaking abstract – Poster P. 931, page e527

Fertility and Sterility, Volume 114, No. 3, Supplement, September 2020, Poster session, Late-breaking abstract – Poster P. 931, page e527

Read more

Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist

October 12, 2020

Linzagolix

Jacques Donnez, M.D., Ph.D., Marie-Madeleine Dolmans, M.D., Ph.D.

Fertility and Sterility, Volume 114, Issue 4, 2020, Pages 739-741

Read more

The mechanism of action of oxytocin receptor antagonists (OTRan) in ART – a study of nolasiban on biomarkers of uterine receptivity in healthy female volunteers

July 13, 2020

Nolasiban

O. Pohl, L. Marchand, P. Pierzyński, C. Blockeel, S. Mackens, U. Lorch, J.P. Gotteland

ESHRE 36th Virtual Annual Meeting, 5-8 July 2020

Human Reproduction, Volume 35, Issue Supplement_1, July 2020, on pages i83–i84

Read more

Efficacy and safety of linzagolix on heavy menstrual bleeding (HMB) due to uterine fibroids (UF): Results from a placebo-controlled, randomized, Phase 3 trial

Linzagolix

H. Taylor, J. Donnez, R. Taylor, E. Bestel, J.P. Gotteland, A. Humberstone, E. Garner

ESHRE 36th Virtual Annual Meeting, 5-8 July 2020

Human Reproduction, Volume 35, Issue Supplement_1, July 2020, on page i13

Read more

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial

June 4, 2020

Linzagolix

Jacques Donnez, M.D., Ph.D., Hugh S. Taylor, M.D., Ph.D., Robert N. Taylor, M.D., Ph.D., Mark D. Akin, M.D., Tatyana F. Tatarchuk, M.D., Dr. Sc., Krzysztof Wilk, M.D., Jean-Pierre Gotteland, Ph.D., Veronique Lecomte, Pharm.D., Elke Bestel, M.D.

Published online: June 03, 2020

Donnez, Jacques et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertility and Sterility, Volume 114, Issue 1, July 2020, Pages 44-55

Read more